Abion announced on the 28th that it will participate in the '2024 BIO-Europe Fall' to be held in Stockholm, Sweden from the 4th to the 6th of next month.
Selected as a presenting company, Abion will focus on its pipeline products ABN202 and ABN501. In addition, it plans to introduce major research and development (R&D) achievements and conduct business development (BD) partnering with multinational pharmaceutical and biotech companies as well as academic researchers.
The Antibody Cytokine Fusion Protein (ACFP) platform ABN202, which fuses interferon-beta variants with tumor-targeting antibodies, demonstrated excellent anticancer effects in various solid tumor preclinical models. ACFP is gaining attention as a new therapeutic strategy that overcomes resistance mechanisms of conventional antibody-drug conjugates (ADC).
Abion will also introduce ABN501, the world's only claudin-3 targeting antibody therapeutic. ABN501 is currently under joint research based on a research and development partnership with the National Cancer Institute (NCI) under the U.S. National Institutes of Health (NIH).
A company representative stated, "We will explore collaboration possibilities through one-on-one partnering with industry stakeholders and institutional investors to strengthen our position in the global market," adding, "We will strive to generate various achievements at the event."
Meanwhile, BIO-Europe is the world's largest biotech partnering event. Through the Partnering ONE platform, companies and representatives from over 60 countries can hold one-on-one meetings. This year, more than 5,000 potential partners are expected to participate, with licensing deals, investment attraction, and global networking anticipated.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
